☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Gastrointestinal Disorders
Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastroin...
June 10, 2020
Takeda Collaborates with Cerevance to Develop New Therapies for Gastrointestinal Disorders
December 18, 2019
Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders
May 16, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
